Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Celgene
Manali Kamdar; Scott R Solomon; Jon Arnason; Patrick B Johnston; Bertram Glass; Veronika Bachanova; Sami Ibrahimi; Stephan Mielke; Pim Mutsaers; Francisco Hernandez-Ilizaliturri; Koji Izutsu; Franck Morschhauser; Matthew Lunning; David G Maloney; Alessandro Crotta; Sandrine Montheard; Alessandro Previtali; Lara Stepan; Ken Ogasawara; Timothy Mack; Jeremy S Abramson; TRANSFORM Investigators